medigraphic.com
Academia Mexicana de Neurología, A.C.

2010, Number 3

<< Back Next >>

Rev Mex Neuroci 2010; 11 (3)

Neuroanatomical interpretation of the main motor symptoms and non-motor symptoms in Parkinson’s disease

Calderón Álvarez-Tostado JL, Bolaños-Jiménez R, Carrillo-Ruiz JD, Rivera-Silva G

Language: Spanish
References: 41
Page: 218-225
PDF size: 67.38 Kb.


ABSTRACT

Parkinson’s disease is one of the most complex and interesting affections of the central nervous system. Since its description in 1817 by James Parkinson, the cause of the malady is still a mystery, but research in this field is intense and constant scientific breakthroughs help to clarify the perspective. Nowadays there is no curative treatment available for the disease and we only count with palliative therapies to alleviate symptoms, therefore it is necessary to understand profoundly the nervous structures involved in its genesis, that way we will be able to find a cure for the malady. In this article we present an actualized review of the main affected neuroanatomic pathways and their clinical translation into motor and non-motor symptoms.


REFERENCES

  1. González-Torres LC, Armendáriz–Borunda J. Aspectos inmunológicos en la enfermedad de Parkinson. Arch Neurocien (Mex) 2005; 10: 168-9.

  2. Jellinger KA. The Pathology of Parkinson’s disease. Adv Neurol 2001; 86: 55-72.

  3. Forno LS. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996; 55: 259-72.

  4. Gelb DG, Oliver E, Gilman S, Lees AJ. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9.

  5. Lees AJ. The Parkinson chimera. Neurology 2009; 72(Suppl. 2): S2- S11.

  6. Braak H, Del Tredici K, Rub U, de Ros RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.

  7. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson’s disease. Neurology 2009; 72(Suppl. 4): S1- S136.

  8. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson’s disease. Lancet Neurol 2006; 5: 796-802.

  9. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993; 50: 140-8.

  10. Kuhn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider GH, et al. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain 2004; 127: 735-46.

  11. Kuhn AA, Kupsch A, Schneider GH, Brown P. Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J Neurosci 2006; 23: 1956-60.

  12. Berardelli A, Rothwell JC, Thompson PD, Hallet M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 2001; 124: 2131-46.

  13. Bagheri H, Damase-Michael C, Lapeyre-Mestre M, Cismondo S, O’Conell D, Senard JM, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999; 67: 624-9.

  14. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006; 21: 1856-63.

  15. Djaldetti R, Melamed E. Camptocormia in Parkinson’s disease: new insights. J Neurol Neurosurg Psychiatry 2006; 77: 1205.

  16. Kunzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. Brain Res 1975; 88: 195- 209.

  17. Jones EG, Coulter JD, Burton H, Porter R. Cells of origin and terminal distribution of corticostriatal fibers arising in the sensory-motor cortex of monkeys. J Comp Neurol 1977; 173(1): 53-80.

  18. De Long MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-4.

  19. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000; 41(2): 167-84.

  20. Nicholson G, Pereira AC, Hall GM. Parkinson’s disease and anesthesia. Br J Anaesth 2002; 89: 904-16.

  21. Lang AE, Lozano AM. Parkinson’s disease: second of two parts. N Engl J Med 1998; 339: 1130-43.

  22. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia — normal and in Parkinson’s disease. J Chem Neuroanat 2001; 22: 3-12.

  23. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.

  24. Bloem BR. Postural instability in Parkinson’s disease. Clin Neurol Neurosurg 1992; 94: S41-S45.

  25. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56: 1712-21.

  26. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19: 871-84.

  27. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. TINS 1990; 13(7): 266-71.

  28. Thomas RJ. Blinking and the release reflexes: are they clinically useful? J Am Geriatr Soc 1994; 42: 609-13.

  29. Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology 2004; 63: 1096-8.

  30. Hunker CJ, Abbs JH, Barlow SM. The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: a quantitative analysis. Neurology 1982; 32: 749-54.

  31. Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson’s disease. Exp Rev Neurother 2006; 6: 1811-22.

  32. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophtalmologic features of Parkinson’s disease. Neurology 2004; 62: 177-80.

  33. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.

  34. Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ, Doyon B, et al. Abnormal ocular movements in Parkinson’s disease: evidence for involvement of dopaminergic systems. Brain 1989; 112: 1193-214.

  35. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001; 57: 1392-6.

  36. Gagnon JF, Postuma BB, Mazza S, Doyon J, Montplaisir J. Rapid-eyemovement sleep behavior disorder and neurodegenerative diseases. Lancet Neurol 2006; 5: 424-32.

  37. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 2007; 130: 1586-95.

  38. Ishizaki F, Kito S. Definition and classification of neurotransmitters. Nippon Rinsho. 42, 779-784 (1984).

  39. Amenta F, Zacchelo D, Collier WL. Neurotransmitters, neuroreceptors and aging. Mechanism of Ageing and Development 1991; 61: 249- 273.

  40. Monographs in neural sciences. Vol. 10, neuroreceptors in health and disease. Marwaha J, Anderson WJ, Krager S (eds.). 1984. Trends in Pharmacological Sciences. Vol. 6. 1985, p. 138-9.

  41. Usdin E, Bunney WEJr, Davis, Wiley SJ. Neuroreceptors: Basic and Clinical Aspects. Usdin E, Bunney WEJr, Davis, Wiley SJ (eds.). 1981. Trends in Neurosciences. Vol. 5. 1982, p. 251.




2020     |     www.medigraphic.com